Camille Lee is Head of U.S. Immunology.  Leading the immunology business in the U.S., Camille is committed to transforming our business to deliver maximum value to patients living with autoimmune and inflammation-related diseases in the United States.  

Camille brings to UCB more than 30 years of experience in the pharmaceutical industry. She started her career as a sales representative. Prior to joining UCB, Camille was senior vice president at Biogen in the global Alzheimer’s disease therapy area. There, she was responsible for the global Alzheimer’s portfolio strategy as well as leading the project development and commercialization of the lead asset, aducanumab.

Camille has spent the majority of her career at Novo Nordisk, where she started as a sales representative and progressed with increasing levels of responsibility both in the U.S. and globally, in the areas of marketing, managed markets, operations, strategic launch planning and sales management.  Most recently, she was the senior vice president for diabetes and obesity marketing in the U.S. During her tenure, she was directly involved in more than seven global and U.S. product launches – most notably Victoza (liraglutide) and Tresiba (degludec) for diabetes and Saxenda (liraglutide) for obesity. While leading the U.S. marketing organization, she established the development of a patient-centric team that was recognized by patients and industry for innovative approaches with patient and caregiver engagement.

Camille received her bachelor of science degree in business administration from California State University Long Beach.  She also holds an E*MBA from the Scandanavian Management Institute in Copenhagen Denmark. She enjoys traveling, exploring new cultures, the outdoors, water-related activities, and treasures time with family and friends.

 

Download Bio